Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PGR | P06401 | 4/20 | 0.50 |
| ▸ | CA12 | O43570 | 2/20 | 0.50 |
| ▸ | CA1 | P00915 | 2/20 | 0.50 |
| ▸ | CA2 | P00918 | 2/20 | 0.50 |
| ▸ | NR3C1 | P04150 | 2/20 | 0.50 |
| ▸ | NR3C2 | P08235 | 2/20 | 0.50 |
| ▸ | AR | P10275 | 2/20 | 0.50 |
| ▸ | CA3 | P07451 | 1/20 | 0.50 |
| ▸ | CA6 | P23280 | 1/20 | 0.50 |
| ▸ | CA5A | P35218 | 1/20 | 0.50 |
| ▸ | CA7 | P43166 | 1/20 | 0.50 |
| ▸ | CA9 | Q16790 | 1/20 | 0.50 |
| ▸ | CRBN | Q96SW2 | 1/20 | 0.50 |
| ▸ | CA14 | Q9ULX7 | 1/20 | 0.50 |
| ▸ | CA5B | Q9Y2D0 | 1/20 | 0.50 |
| ▸ | ACLY | P53396 | 1/20 | 0.47 |
| ▸ | BRPF1 | P55201 | 1/20 | 0.47 |
| ▸ | CCR2 | P41597 | 1/20 | 0.47 |
| ▸ | MEN1 | O00255 | 2/20 | 0.46 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3067241 | 0.83 | CA1 (0.70) | PGRCA12CA1CA2NR3C1 | |
| SCHEMBL3064612 | 0.79 | CA12 (0.52) | PGRCA12CA1CA2NR3C1 | |
| SCHEMBL3068945 | 0.78 | CRBN (0.54) | PGRCA12CA1CA2NR3C1 | |
| SCHEMBL31307400 | 0.74 | KDM4E (0.66) | CA12CA1CA2CA3CA6 | |
| SCHEMBL28523161 | 0.74 | KDM4E (0.66) | CA12CA1CA2CA3CA6 | |
| SCHEMBL7491194 | 0.73 | BRD4 (0.57) | PGRNR3C1ACLYMEN1KMT2A | |
| SCHEMBL3063809 | 0.73 | CA1 (0.63) | CA12CA1CA2CA3CA6 | |
| SCHEMBL31307411 | 0.73 | CA12 (0.60) | CA12CA1CA2CA3CA6 | |
| SCHEMBL22450841 | 0.73 | NR4A2 (0.69) | BRPF1KDM4EALDH1A1NR4A2HDAC3 | |
| SCHEMBL3051463 | 0.72 | CA12 (0.52) | PGRCA12CA1CA2NR3C1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 17 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7834049-B2 | Sulfonamide compound for treating arteriosclerosis, psoriasis, colon cancer, retinal angiogenesis, diabetic retinopathy or inflammatory diseases | EISAI R&D MANAGEMENT CO., LTD. (JP) | 2010-11-16 | — | — | US | disclosed |
| US-20100267754-A1 | INTEGRIN EXPRESSION INHIBITOR | WAKABAYASHI TOSHIAKI | 2010-10-21 | — | — | US | disclosed |
| EP-1433479-B1 | APPETITE-STIMULATING AGENTS AND REMEDIES FOR ANOREXIA | EISAI R&D MAN CO LTD (JP) | 2007-12-05 | — | — | EP | disclosed |
| US-7015241-B2 | Appetite-stimulating agents and remedies for anorexia | EISAI CO., LTD. (JP) | 2006-03-21 | — | — | US | disclosed |
| CN-1221533-C | Heterobicyclic sulfonamide derivative and sulfonic ester derivative | EISAI CO LTD (JP) | 2005-10-05 | — | — | CN | disclosed |
| US-20050176712-A1 | Integrin expression inhibitor | EISAI CO., LTD. | 2005-08-11 | — | — | US | disclosed |
| US-20040242628-A1 | Appetite-stimulating agents and remedies for anorexia | EISAI R&D MANAGEMENT CO., LTD. (JP) | 2004-12-02 | — | — | US | disclosed |
| US-20040235866-A1 | Lymphocytic activation inhibitor and remedial agent for autoimmune disease | EISAI R&D MANAGEMENT CO., LTD. (JP) | 2004-11-25 | — | — | US | disclosed |
| EP-1433479-A1 | APPETITE-STIMULATING AGENTS AND REMEDIES FOR ANOREXIA | Eisai Co., Ltd (JP) | 2004-06-30 | — | — | EP | disclosed |
| EP-1430894-A1 | LYMPHOCYTIC ACTIVATION INHIBITOR AND REMEDIAL AGENT FOR AUTOIMMUNE DISEASE | Eisai Co. Ltd (JP) | 2004-06-23 | — | — | EP | disclosed |
| CN-1491941-A | Heterobicyclic sulfonamide derivative and sulfonic ester derivative | ������������ʽ���� | 2004-04-28 | — | — | CN | disclosed |
| US-20040018192-A1 | Integrin expression inhibitors | EISAI CO., LTD. (JP) | 2004-01-29 | — | — | US | disclosed |
| EP-0673937-B1 | BICYCLIC HETEROCYCLIC SULFONAMIDE AND SULFONIC ESTER DERIVATIVES | EISAI CO LTD (JP) | 2003-11-26 | — | — | EP | disclosed |
| EP-1258252-A1 | INTEGRIN EXPRESSION INHIBITORS | Eisai Co., Ltd. (JP) | 2002-11-20 | — | — | EP | disclosed |
| CN-1079097-C | Heterobicyclic sulfonamide derivatives and sulfonate derivatives | EISAI CO LTD (JP) | 2002-02-13 | — | — | CN | disclosed |
| CN-1114506-A | Heterobicyclic sulfonamide derivatives and sulfonate derivatives | EISAI CO LTD (JP) | 1996-01-03 | — | — | CN | disclosed |
| EP-0673937-A1 | BICYCLIC HETEROCYCLIC SULFONAMIDE AND SULFONIC ESTER DERIVATIVES | Eisai Co., Ltd. (JP) | 1995-09-27 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050176712-A1 | Integrin expression inhibitor | ITGB5, ITGB1, ITGB2 | PGR 1305/4885CA12 513/4885CA1 867/4885 |
| US-20040235866-A1 | Lymphocytic activation inhibitor and remedial agent for autoimmune disease | NFATC1, CHUK, CD4 | PGR 3500/4885CA12 607/4885CA1 44/4885 |
| US-20100267754-A1 | INTEGRIN EXPRESSION INHIBITOR | ITGB5, ITGB1, ITGB2 | PGR 1305/4885CA12 513/4885CA1 867/4885 |
| US-20040242628-A1 | Appetite-stimulating agents and remedies for anorexia | GHSR, CCKAR, SUCNR1 | PGR 1357/4885CA12 452/4885CA1 219/4885 |
| US-20040018192-A1 | Integrin expression inhibitors | ITGB1, ITGB4, ITGB5 | PGR 1278/4885CA12 535/4885CA1 827/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.